Positive first results in DexTechs phase IIb-study for OsteoDex

9 February, 2017

The study has the title “A randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases” and is conducted in Sweden (Norrlands University Hospital, Umeå, South General Hospital in Stockholm and Örebro University Hospital), in Finland (Tampere University Hospital), in Estonia (East Tallinn Central Hospital and Tartu University Hospital) and in Latvia (Riga East University Hospital and Daugavpils Regional Hospital).

Every second month samples are sent to Karolinska Hospital, Clinical Chemistry lab in Stockholm for analysis of markers related to the activity in the patient’s bone metastasis, so called key analytes.  

The company has now evaluated the first analysis results and concludes an early trend showing that either the bone marker values remain normal or are decreasing within normal range or when abnormal at base line, decrease to normal range.

The recruitment status is estimated to be good with about 1/3 of the total planned patients (60) screened resulting in 15 patients randomized for active treatment. The company estimate that the whole year 2017 will be needed for the study to be fully recruited, i.e. slightly delayed compared to earlier prognosis (Q2 2017). The company pertains to issue regular information on study status and significant findings. The budget situation remains satisfactory.


 “Even though the results are yet only from a smaller number of patients the results are promising. For everybody involved in the study, its positive to have early indications that the treatment is efficacious, not the least for the patients, says CEO Anders R Holmberg.”



For additional information

Gösta Lundgren – CFO & Investor Relations

DexTech Medical AB

Tel.: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com


This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on February 8, 2017.